Jpmorgan Chase & CO Hcw Biologics Inc. Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
A detailed history of Jpmorgan Chase & CO transactions in Hcw Biologics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 9 shares of HCWB stock, worth $5. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9
Previous 83
89.16%
Holding current value
$5
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HCWB
# of Institutions
21Shares Held
1.1MCall Options Held
0Put Options Held
0-
High Tower Advisors, LLC Chicago, IL180KShares$116,8760.0% of portfolio
-
Avantax Planning Partners, Inc.180KShares$116,8550.01% of portfolio
-
Geode Capital Management, LLC Boston, MA174KShares$113,2840.0% of portfolio
-
Cresset Asset Management, LLC Chicago, IL132KShares$85,7930.0% of portfolio
-
Pullen Investment Management, LLC Bradenton, FL85.1KShares$55,3250.13% of portfolio
About HCW Biologics Inc.
- Ticker HCWB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,833,100
- Market Cap $23.3M
- Description
- HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal...